Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Vaccination in Leishmaniasis: A Review Article Publisher Pubmed



Abdellahi L1 ; Iraji F2 ; Mahmoudabadi A3 ; Hejazi SH4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Department of Dermatology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. School of Medicine, Augusta University, UGA Partnership, Athens, GA, United States
  4. 4. Skin Diseases and Leishmaniasis Research Center, Department of Parasitology and Mycology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Source: Iranian Biomedical Journal Published:2022


Abstract

Leishmaniasis is caused by protozoan Leishmania parasites that are transmitted through female sandfly bites. The disease is predominantly endemic to the tropics and semi-tropics and has been reported in more than 98 countries. Due to the side effects of anti-Leishmania drugs and the emergence of drug-resistant isolates, there is currently no encouraging prospect of introducing an effective therapy for the disease. Hence, it seems that the key to disease control management is the introduction of an effective vaccine, particularly against its cutaneous form. Advances in understanding underlying immune mechanisms are feasibale using a variety of candidate antigens, including attenuated live parasites, crude antigens, pure or recombinant Leishmania proteins, Leishmania genes encoding protective proteins, as well as immune system activators from the saliva of parasite vectors. However, there is still no vaccine against different types of human leishmaniasis. In this study, we review the works conducted or being performed in this field. © 2022, Pasteur Institute of Iran. All rights reserved.
Related Docs
View other Related Docs
1. Evaluation of Live Recombinant Nonpathogenic Leishmania Tarentolae Expressing Cysteine Proteinase and A2 Genes As a Candidate Vaccine Against Experimental Canine Visceral Leishmaniasis, PLoS ONE (2015)
2. From Classical Approaches to New Developments in Genetic Engineering of Live Attenuated Vaccine Against Cutaneous Leishmaniasis: Potential and Immunization, Frontiers in Public Health (2024)
3. Immunological Comparison of Dna Vaccination Using Two Delivery Systems Against Canine Leishmaniasis, Veterinary Parasitology (2015)
4. Induction of Immune Responses by Dna Vaccines Formulated With Dendrimer and Poly (Methyl Methacrylate) (Pmma) Nano-Adjuvants in Balb/C Mice Infected With Leishmania Major, Open Access Macedonian Journal of Medical Sciences (2018)
5. Leishmania Vaccines Entered in Clinical Trials: A Review of Literature, International Journal of Preventive Medicine (2019)
6. The Role of Liposomal Cpg Odn on the Course of L. Major Infection in Balb/C Mice, Iranian Journal of Parasitology (2010)
7. Leishmanization: Use of an Old Method for Evaluation of Candidate Vaccines Against Leishmaniasis, Vaccine (2005)
8. A Lentiviral Vaccine Expressing Kmp11-Haspb Fusion Protein Increases Immune Response to Leishmania Major in Balb/C, Parasitology Research (2018)
Experts (# of related papers)
View all Related Experts
Seyed Hossein Hejazi (63)
Sedighe Saberi (13)
Other Related Docs
9. Immunization Against Leishmania Major Using Uv-Irradiated Promastigote in Experimental Model Balb/C Mice, Biochemical and Cellular Archives (2017)
10. Evaluation of a Novel Lentiviral Vaccine Expressing Kmp11-Haspb Fusion Protein Against Leishmania Infantum in Balb/C Mice, Parasite Immunology (2016)
11. Engineering a Multi-Epitope Vaccine Candidate Against Leishmania Infantum Using Comprehensive Immunoinformatics Methods, Biologia (2022)
12. A Randomised, Double-Blind, Controlled Trial of a Killed L. Major Vaccine Plus Bcg Against Zoonotic Cutaneous Leishmaniasis in Iran, Vaccine (1999)
13. Parasites and Immunotherapy: With or Against?, Journal of Parasitic Diseases (2016)
14. Tlr2 and Tlr4 in Cutaneous Leishmaniasis Caused by Leishmania Major, Scandinavian Journal of Immunology (2013)
15. Comparison of Protein Profile of Killed and Autoclaved Leishmania Major Using Polyacrylamide Gel Electrophoresis, Journal of Isfahan Medical School (2013)
16. Evaluation of Expression Variations in Virulence-Related Genes of Leishmania Major After Several Culture Passages Compared With Phlebotomus Papatasi Isolated Promastigotes, PLoS ONE (2023)
17. The Role of Bcg in Human Immune Responses Induced by Multiple Injections of Autoclaved Leishmania Major As a Candidate Vaccine Against Leishmaniasis, Vaccine (2002)
18. Comparative Study on the Effectiveness of Coumavec® and Zinc Phosphide in Controlling Zoonotic Cutaneous Leishmaniasis in a Hyperendemic Focus in Central Iran, Journal of Arthropod-Borne Diseases (2012)
19. Randomised Vaccine Trial of Single Dose of Killed Leishmania Major Plus Bcg Against Anthroponotic Cutaneous Leishmaniasis in Bam, Iran, Lancet (1998)
20. Immune Response Measured in Human Volunteers Vaccinated With Autoclaved Leishmania Major Vaccine Mixed With Low Dose of Bcg, Clinical and Experimental Immunology (2003)
21. Demographic and Clinical Characteristics of Children With Cutaneous Leishmaniasis in Isfahan Province, Iran, During 2011-2015, Journal of Isfahan Medical School (2017)
22. Therapeutic Effect of Topical Tamoxifen in Murine Cutaneous Leishmaniasis Caused by Leishmania Major, Antimicrobial Agents and Chemotherapy (2024)
23. Immunology and Genetic of Leishmania Infantum: The Role of Endonuclease G in the Apoptosis, Journal of Research in Medical Sciences (2018)
24. Population Structure of Leishmania Tropica Causing Anthroponotic Cutaneous Leishmaniasis in Southern Iran by Pcr-Rflp of Kinetoplastid Dna, BioMed Research International (2018)
25. Emerging of Cutaneous Leishmaniais Due to Leishmania Major in a New Focus in Esfahan Province, Central Iran, Journal of Arthropod-Borne Diseases (2020)
26. Combinatorial Delivery of Antigen and Tlr Agonists Via Plga Nanoparticles Modulates Leishmania Major-Infected-Macrophages Activation, Biomedicine and Pharmacotherapy (2021)
27. Interleukin-10 and Transforming Growth Factor-Β in Early and Late Lesions of Patients With Leishmania Major Induced Cutaneous Leishmaniasis, Iranian Journal of Parasitology (2012)
28. Leishmanicidal Activity of Films Containing Paromomycin and Gentamicin Sulfate Both in Vitro and in Vivo, Iranian Journal of Parasitology (2011)
29. Comparison of Three Different Therapies for Cutaneous Leishmaniasis and Identification of the Etiologic Isolates in Isfahan, Iran, Archives of Iranian Medicine (2020)
30. Differential Expression Profiles of the Salivary Proteins Sp15 and Sp44 From Phlebotomus Papatasi, Parasites and Vectors (2016)
31. Interleukin-10 and Transforming Growth Factor-Β in Early and Late Lesions of Patients With Leishmania Major Induced Cutaneous Leishmaniasis, Iranian Journal of Parasitology (2012)
32. Development of Liposomes Loaded With Anti-Leishmanial Drugs for the Treatment of Cutaneous Leishmaniasis, Journal of Liposome Research (2013)
33. Antimonial Treatment Failure Rate in Patients With Cutaneous Leishmaniasis, Tehran University Medical Journal (2018)
34. Effect of Combination Therapy With Systemic Glucantime and Pentoxifylline in the Treatment of Cutaneous Leishmaniasis, International Journal of Dermatology (2006)
35. A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Itraconazole in the Treatment of Cutaneous Leishmaniasis, Journal of the European Academy of Dermatology and Venereology (2005)
36. Effect of Leishmania Gerbilli Injection on Mice Immunization Against Cutaneous Leishmaniasis (Cl) Caused by Leishmania Major, Pakistan Journal of Biological Sciences (2007)
37. Exposure to Leishmania Major Modulates the Proportion of Cd4+ T Cells Without Affecting Cellular Immune Responses, Microbiology and Immunology (2007)
38. Field Evaluation of Phostoxin and Zinc Phosphide for the Control of Zoonotic Cutaneous Leishmaniasis in a Hyperendemic Area, Central Iran, Journal of Vector Borne Diseases (2014)
39. Regulatory T-Cell Profile in Early and Late Lesions of Cutaneous Leishmaniasis Due to Leishmania Major, Journal of Research in Medical Sciences (2012)
40. Evaluation of Leishmanin Skin Test and Its Relationship With the Clinical Form and Duration of Cutaneous Leishmaniasis, Dermatology Online Journal (2006)
41. Anti-Leishmaniasis Effect of Staphylococcus Aureus Protein a on the Size of the Lesion and Parasitic Load, Advanced Biomedical Research (2023)
42. Evaluation of Leishmanin Skin Test Reaction in Different Variants of Cutaneous Leishmaniasis, Indian Journal of Dermatology (2013)
43. An Outbreak of Cutaneous Leishmaniasis Due to Leishmania Major in an Endemic Focus in Central Iran, Journal of Parasitic Diseases (2022)
44. Detection of Leishmania Parasites From Cutaneous Leishmaniasis Patients With Negative Direct Microscopy Using Nnn and Pcr-Rflp, Journal of Isfahan Medical School (2012)
45. The Potential Role of Protein Disulfide Isomerases (Pdis) During Parasitic Infections: A Focus on Leishmania Spp., Pathogens and Disease (2023)
46. Evaluation of the Biodiversity and Distribution of Sand Flies and Tracking of Leishmania Major in Them in Central Iran, International Journal of Environmental Health Research (2024)
47. Identification of Leishmania Species and Treatment Courses in Patients With Leishmaniasis in Isfahan, Iran, Journal of Isfahan Medical School (2012)
48. Anti-Leishmania Activity of Osthole, Pharmacognosy Research (2016)
49. Regulatory T-Cell Profile in Early and Late Lesions of Cutaneous Leishmaniasis Due to Leishmania Major, Journal of Isfahan Medical School (2014)
50. Pcr-Rflp Diagnosis and Characterization of Leishmania Species Causing Human Cutaneous Leishmaniasis and Evaluation of Treatment Times With Glucantime in These Patients, Tropical Biomedicine (2016)